Skip to Content

Clinical Trial Details

Rivaroxaban VTE Prophylaxis

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Cancer
Study Type: Interventional
Phase: Phase III
Study Start Date: 09/18/2015
Study Completion Date: 01/31/2018

The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult participants with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.

NCT Number
NCT02555878
Principal Investigator(s)
Cheryl A. Aylesworth, MD
Sponsor(s)
Janssen Research & Development, LLC
Participant Eligibility
  • Age: 18 - No Maximum
  • Gender: Male, Female

Location

  • Shady Grove Adventist Aquilino Cancer Center
    9905 Medical Center Drive
    Rockville, MD 20850
    Main: 240-826-6297

Clincal Trials & Research Studies

Patient Stories

We’re writing new chapters in the lives of our patients, their families and our community daily. These are their stories:

Local Health News - In Your Inbox

Join over 47k of your friends & neighbors and get the latest news about community health programs and events when you sign-up for Adventist HealthCare & You Digital.

Subscribe Today!